NCT03300960View on ClinicalTrials.gov

Usefulness of Medroxyprogesterone Acetate in Follicular Phase in Oocyte Donors. Undergoing Ovarian Stimulation

PHASE3CompletedINTERVENTIONAL
Enrollment

318

Participants

Timeline

Start Date

October 20, 2017

Primary Completion Date

June 25, 2019

Study Completion Date

June 25, 2019

Conditions
Infertility
Interventions
DRUG

Provera 10 mg.

One 10 mg tablet of MPA (Medroxyprogesterone acetate) is administered every 24 hours from the onset of Controlled Ovarian Stimulation (COS), until the day of triggering.

DRUG

Ganirelix (GnRH antagonist)

One ampoule of Ganirelix (GnRH antagonist) a day once diameter of follicles are 14 mm diameter on average until triggering.

Trial Locations (1)

46015

IVI Valencia, Valencia

All Listed Sponsors
lead

Instituto Valenciano de Infertilidad, IVI VALENCIA

OTHER

NCT03300960 - Usefulness of Medroxyprogesterone Acetate in Follicular Phase in Oocyte Donors. Undergoing Ovarian Stimulation | Biotech Hunter | Biotech Hunter